Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.
This page contains content from the copyrighted Wikipedia article "Pexelizumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.